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Background and Purpose  Cluster headache (CH) can present with migrainous symptoms 
such as nausea, photophobia, and phonophobia. In addition, an overlap between CH and mi-
graine has been reported. This study aimed to determine the differences in the characteristics 
of CH according to the presence of comorbid migraine.
Methods  This study was performed using data from a prospective multicenter registry study 
of CH involving 16 headache clinics. CH and migraine were diagnosed by headache specialists 
at each hospital based on third edition of the International Classification of Headache Disor-
ders (ICHD-3). We interviewed patients with comorbid migraine to obtain detailed informa-
tion about migraine. The characteristics and psychological comorbidities of CH were com-
pared between patients with and without comorbid migraine.
Results  Thirty (15.6%) of 192 patients with CH had comorbid migraine, comprising 18 with 
migraine without aura, 1 with migraine with aura, 3 with chronic migraine, and 8 with proba-
ble migraine. Compared to patients with CH without migraine, patients with CH with comor-
bid migraine had a shorter duration of CH after the first episode [5.4±7.4 vs. 9.0±8.2 years 
(mean±standard deviation), p=0.008], a lower frequency of episodic CH (50.0% vs. 73.5%, p= 
0.010), and a higher frequency of chronic CH (13.3% vs. 3.7%, p=0.033). Psychiatric comorbidi-
ties did not differ between patients with and without comorbid migraine. The headaches expe-
rienced by patients could be distinguished based on their trigeminal autonomic symptoms, 
pulsating character, severity, and pain location.
Conclusions  Distinct characteristics of CH remained unchanged in patients with comorbid 
migraine with the exception of an increased frequency of chronic CH. The most appropriate man-
agement of CH requires clinicians to check the history of preceding migraine, particularly in cases 
of chronic CH.
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Differences in Characteristics and Comorbidity 
of Cluster Headache According to the Presence of Migraine
INTRODUCTION
Cluster headache (CH) is a rare primary headache disorder with very severe pain charac-
terized by autonomic symptoms and periodicity, and is the most common type of head-
ache categorized under trigeminal autonomic cephalagia.1 Most patients with CH are classi-
fied as having episodic CH since they have a headache-free period of several months or even 
years, the so-called remission period. Those patients without such a long remission period 
are classified as having chronic CH.1-3
An overlap between CH and migraine has been reported. In addition to autonomic 
symptoms, 25–46% of patients with CH experience and report migraine-like features such 
as nausea, photophobia, phonophobia, and sometimes migraine itself.4-6 Furthermore, CH 
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and migraine may share common clinical features such as 
unilateral pain location, similar triggering factors (histamine, 
calcitonin-gene-related peptide, or nitrate), a triptan re-
sponse, and the treatment effect of neuromodulation.7-9 
Moreover, a possible genetic link between CH and migraine 
has also been reported.10 Underlying migraine can delay the 
diagnosis of CH, which is of concern since the main abor-
tive and preventive medications differ for the two disorders. 
Thus, both accurately diagnosing CH and distinguishing 
CH from migraine are essential to the correct management 
of CH. In addition, comorbidity of CH and migraine may 
reveal common neurobiological mechanisms. 
A few studies have investigated the coincidence of CH and 
migraine, with comorbid migraine reportedly being present 
in 10–16.7% of patients with CH.4,11,12 However, the differ-
ences between the characteristics of CH and migraine have 
not been evaluated adequately. Several other aspects also re-
main unknown, such as the times of onset of CH and migraine, 
clinical parameters for differentiation, and treatment pat-
tern for migraine in patients who suffer from both migraine 
and CH. In this study we aimed to determine the differences 
in the characteristics and comorbidities of CH according to 
the history of preceding migraine, and to elucidate the de-
tailed history of migraine in patients with CH.
METHODS
Subjects
The Korean Cluster Headache Registry (KCHR) is a prospec-
tive, multicenter, observational, registry-based study that in-
cluded patients with CH at 16 hospitals in Korea between Sep-
tember 2016 and July 2018.13 In the present study, we included 
adult patients who were diagnosed as having CH (episodic, 
chronic, or probable CH) based on the judgment of the neu-
rology board members. CH was diagnosed based on the third 
edition of the International Classification of Headache Dis-
orders, 3rd edition beta version (ICHD-3 beta).14 Patients who 
were unable to communicate in Korean, who were unable to 
give reliable answers to questionnaires due to psychiatric rea-
sons or cognitive decline at the time of the investigator’s deci-
sion, or who were included in other clinical studies were not 
registered in the KCHR.13,15 For our substudy we enrolled 
only those KCHR participants with CH compatible with the 
ICHD-3.1 Our study was approved by an Internal Review 
Board and a local ethics committee at each hospital (2016–
396-I). All patients enrolled in the KCHR had already pro-
vided written informed consent, and all procedures complied 
with the tenets of the Declaration of Helsinki and Good 
Clinical Practice guidelines.
Details of the KCHR
We have previously reported on the detailed protocol of the 
KCHR.13,16 The clinical data collected about the last ictal pe-
riod included sex, age at onset, body mass index, time to di-
agnosis of CH from the first headache onset, CH severity on 
a numeric rating scale (from 0 to 10), frequency of CH, mean 
duration of CH since the first episode, bout duration of CH 
during the ictal period, total number of CH bouts, smoking 
history (current smoker, ex-smoker, or never smoked), al-
cohol intake, headache impact (Headache Impact Test-6; 
HIT-6), anxiety (General Anxiety Disorder-7 scale; GAD-7), 
depression (Patient Health Questionnaire-9; PHQ-9), stress 
(Short-Form Perceived Stress Scale-4; PSS-4), quality of life 
(EuroQol: EQ-5D health utility score), and cutaneous allo-
dynia (Allodynia Symptoms Scale-12).17-20 The bout dura-
tion was defined as the duration between the first day to the 
last day of cluster periods in which cluster attacks occurred 
in series lasting for weeks or months separated by remission 
periods, which usually lasted several months or even years.1 
The total number of bouts was defined as total number of 
developing bout (cluster period) diagnosed as the CH. For 
all participants the investigators ascertained the presence of 
comorbid migraine based on the ICHD-3. The type of mi-
graine was classified into migraine without aura, migraine 
with aura, chronic migraine, and probable migraine.1
Migraine substudy
We performed a comprehensive face-to-face or telephonic 
interview with each patient who agreed to participate to ob-
tain further information about migraine and its relationship 
with CH. Furthermore, we assessed time parameters for diag-
nosing CH and migraine, clinical parameters for differentiat-
ing between patients with CH with and without migraine, and 
curative and preventive medications for migraine.
Statistical analysis
IBM SPSS Statistics software (version 20.0 for Windows, IBM 
Corporation, Armonk, NY, USA) was used for statistical 
analysis. Kolmogorov-Smirnov tests were performed to inves-
tigate whether the included variables conformed to a normal 
distribution. The chi-square test and Fisher’s exact test were 
used to compare categorical variables, and the independent 
t-test was used to compare continuous variables. When nor-
mality was not present, continuous variables were analyzed 
using the Mann-Whitney U test or Kruskal-Wallis test. For 
convenience, the presence of migraine was dichotomized into 
with and without migraine regardless of the migraine classi-
fication. A probability value of p<0.05 in two-tailed tests was 
considered statistically significant.
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RESULTS
Comparison between CH with and without 
comorbid migraine 
Among 194 patients identified as having CH based on ICHD-3, 
1 patient was excluded due to not meeting ICHD-3 criteria 
and another patient was excluded due to an uncertain history 
of migraine. We therefore finally analyzed 192 CH patients, 
comprising 26 with their first episode of CH, 134 with episodic 
CH, 10 with chronic CH, and 22 with probable CH. Their age 
was 38.1±10.8 years (mean±standard deviation) and 160 
(83.3%) of them were male. The age at the onset of CH was 
29.6±12.5 years and the CH duration was 8.4± 8.1 years. The 
score on the numeric rating scale for CH severity from the lat-
est ictal period was 8.9±1.2. The frequency of CH was 2.2± 
1.8 per day during the latest ictal period, and the total num-
ber of CH bouts was 8.7±13.2. 
Thirty (15.6%) of the 192 patients with CH had comorbid 
migraine, comprising 18 with migraine without aura, 1 with 
migraine with aura, 3 with chronic migraine, and 8 with prob-
able migraine. The CH duration was shorter in patients with 
CH with comorbid migraine than in those without (5.4±7.4 
vs. 9.0±8.2 years, p=0.008), and the time delay to a CH diag-
nosis was shorter in patients with CH and comorbid migraine 
than in those without migraine (3.2±5.5 vs. 5.9±7.3 years, 
p=0.032). Episodic CH was less common (50.0% vs. 73.5%, 
p=0.010) and chronic CH was more common (13.3% vs. 
3.7%, p=0.033) in patients with CH and comorbid migraine 
than in those without migraine. There were no significant 
differences between the patients with and without comorbid 
migraine in the age at study inclusion (37.6±8.4 vs. 38.2±11.3 
years, p=0.781), age at CH onset (32.2±11.6 vs. 29.2±12.7 
years, p=0.232), or total number of bouts (7.6±10.2 vs. 8.9± 
13.7 years, p=0.625) (Table 1). The following characteristics 
of CH and its comorbidity also did not differ significantly 
between patients with and without migraine history: HIT-6 
score (69.1±7.3 vs. 67.6±8.4, p=0.374), GAD-7 score (8.8± 
6.4 vs. 7.2±5.5, p=0.163), PHQ-9 score (8.9±7.7 vs. 7.1±6.0, 
p=0.170), PSS-4 score (6.6±3.2 vs. 6.7±3.0, p=0.972), and 
EQ-5D score (0.8±0.2 vs. 0.9±0.2, p=0.166) (Table 2). 
Detailed history of migraine and CH 
Nineteen of the 30 patients with CH and comorbid mi-
graine participated in detailed interviews. The age at the 
onset of migraine was 27.6±9.3 years. The onset of migraine 
preceded the onset of CH by 6.5±4.9 years in 12 patients, 
the onset of CH preceded the onset of migraine by 9.7±5.5 
years in 4 patients, and the onset of both conditions occurred 
in the same year in 3 patients. These patients distinguished 
their CH from migraine based on 3.5±1.7 features (range 
1–8 features): trigeminal autonomic symptoms (n=14), pul-
sating character (n=8), severity (n=7), location of pain (n=7), 
timing of pain (n=6), presence of nausea (n=6), premonito-
ry symptoms (just feeling) (n=5), frequency (n=5), phono-
phobia or photophobia (n=4), and agitation (n=4). As cura-
tive medications for migraine, 6 patients took triptans, 11 
took nonsteroidal anti-inflammatory drugs, and 4 took acet-
aminophen, while 1 patient did not take any medication. Eight 
patients reported that the migraine-associated pain was en-
durable and wanted to defer medication use until the cluster pe-
riod, three patients did not take any curative medication, and 
five patients took acetaminophen or acetaminophen-combi-
Table 1. Comparative analysis of demographics according to the history of preceding migraine
Total (n=192) With migraine (n=30) Without migraine (n=162) p
Sex, female 32 (16.7) 9 (30.0) 23 (15.5) 0.062
Age, years 38.1±10.8 37.6±8.4 38.2±11.3 0.781
Body mass index, kg/m2 24.0±3.1 23.0±2.9 24.2±3.2 0.056
Duration of CH, years 8.4±8.1 5.4±7.4 9.0±8.2 0.008
Diagnostic delay time for CH, years 5.5±7.1 3.2±5.5 5.9±7.3 0.032
Age at onset of CH, years 29.6±12.5 32.2±11.6 29.2±12.7 0.232
Total number of CH bouts 8.7±13.2 7.6±10.2 8.9±13.7 0.625
NRS score for CH severity 8.9±1.2 8.8±1.5 9.0±1.2 0.270
Frequency of CH per day 2.2±1.8 2.5±2.2 2.2±1.8 0.475
Classification of CH*
First episode of CH 26 (13.5) 7 (23.3) 19 (11.7) 0.088
Episodic CH 134 (69.8) 15 (50.0) 119 (73.5) 0.010
Chronic CH 10 (5.2) 4 (13.3) 6 (3.7) 0.033
Probable CH 22 (11.5) 4 (13.3) 18 (11.1) 0.726
Data are n (%) or mean±standard-deviation values.
*p value in Fisher’s exact test of 0.028.
CH: cluster headache, NRS: numeric rating scale.
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nation medications. Three patients took preventive medica-
tion for migraine: one took cinnarizine, one took topiramate 
and amitriptyline, and one took candesartan and amitripty-
line. Two patients had a history of episodic tension-type 
headaches additional to CH and migraine.
DISCUSSION
The key findings of our study were as follows: First, 30 (15.6%) 
of the 192 patients had comorbid migraine, and the fre-
quency of chronic CH was higher in patients with comorbid 
migraine than in those without migraine (13.3% vs. 3.7%). 
Second, the clinical characteristics and psychiatric comor-
bidity did not differ according to the presence of comorbid 
migraine in patients with CH. Third, comorbid migraine was 
associated with a shorter duration of CH and shorter delay 
in diagnosing CH. 
To our knowledge, this is the first study to prospectively in-
vestigate migraine comorbidity and its relationship with CH 
in patients with ICHD-3-compatible CH. Migraine is report-
edly present in about one-fourth of patients with CH, but the 
additional diagnosis of migraine based on the ICHD-3 has not 
been evaluated in patients with CH.6 In our study, the preva-
lence of migraine comorbidity was 15.6% in all CH patients, 
and as higher as 40% in patients with chronic CH. Our study 
results are consistent with a Swedish study finding migraine 
in 15.6% of patients with episodic CH and 22.2% of patients 
with chronic CH.12 Regarding the prevalence of chronic CH 
being higher with migraine comorbidity, the traditional hy-
pothesis is that migraines may culminate into CH.21 However, 
both CH and migraine were considered as different clinical 
entities, with either of them potentially leading to the other.11,22 
Furthermore, considering chronicity, a central sensitization 
or biological correlation could result in a closer association 
between chronic CH and migraine.23,24 
In our study we found that most of the clinical parameters 
and psychiatric comorbidities did not differ significantly ac-
cording to the presence of migraine comorbidity, except for 
the disease duration and diagnostic delay time in patients with 
CH. The trigeminovascular system, parasympathetic nerve 
fibers (trigeminal autonomic reflex), and the hypothalamus 
are three key structures associated with CH.7 Despite CH 
and migraine having been categorized as different diseases, 
as mentioned above, CH presents with headache-associated 
symptoms such as nausea, photophobia, and phonophobia 
that are similar to those appearing in migraine. Moreover, 
considering their disease mechanisms, hypothalamus involve-
ment in migraine pathophysiology is also closely associated 
with triggering CH.25 Psychosocial problems including stress 
levels and the daily quality of life of patients with CH have 
not previously been researched in the context of the history 
of migraine comorbidity. In our study, stress and psychiatric 
comorbidities did not differ with the presence of comorbid mi-
graine. These results are in line with previous studies showing 
that the presence of comorbid migraine does not affect the 
pain intensity and clinical characteristics of CH;4,6 further-
more, our results additionally indicate that psychological co-
morbidities do not differ among patients with CH according 
to the presence or absence of comorbid migraine. 
Contrary to the belief that migraine can cause a diagnostic 
delay in CH,26 we found that the headache duration and di-
agnostic delay time were shorter in patients with CH and co-
morbid migraine than in those without migraine comorbidity. 
Although the underlying mechanism remains unclear, this 
may be due to the onset of migraine occurring earlier than 
that of CH, which was reported in two-thirds of patients in-
terviewed in our study; these patients may therefore have fo-
cused more on their headache and sought medical advice, 
Table 2. Comparative analysis of clinical variables according to the history of preceding migraine
Total (n=192) With migraine (n=30) Without migraine (n=162) p 
Smoking history 0.064
Current smoker 82 (42.7) 7 (23.3) 75 (46.3)
Ex-smoker 35 (18.2) 7 (23.3) 28 (17.3)
Never smoked 75 (39.1) 16 (53.3) 59 (36.4)
Alcohol intake, glasses per week 10.3±15.9 3.7±7.9 11.4±16.7 0.001
Headache Impact Test-6 score 67.8±8.2 69.1±7.3 67.6±8.4 0.374
General Anxiety Disorder-7 score 7.4±5.6 8.8±6.4 7.2±5.5 0.163
Patient Health Questionnaire-9 score 7.3±6.2 8.9±7.7 7.1±6.0 0.170
Short-Form Perceived Stress Scale-4 score 6.6±3.0 6.6±3.2 6.7±3.0 0.972
EQ-5D health utility score* 0.8±0.2 0.8±0.2 0.9±0.2 0.166
Allodynia Symptoms Scale-12 score during cluster headache 2.7±3.9 3.7±4.6 2.5±3.8 0.168
Data are n (%) or mean±standard-deviation values.
*Quality of life was assessed by the EQ-5D, three-level instrument and converted into the EQ-5D health utility score.
EQ-5D: EuroQol five-dimension.
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which may have facilitated the early diagnosis of CH. In addi-
tion, our patients with both CH and migraine reported that 
they regarded their migraine headaches as less severe than 
CH. This may have resulted in a difference between the medi-
cations they used for migraine or CH.
Our research was subject to some limitations. First, al-
though we screened a large number of patients with CH who 
were recruited from a multicenter study, only a relatively small 
number of patients with comorbid migraine participated in 
the interview substudy. Thus, our results might not be general-
izable before more patients are investigated in a population-
based study. Second, although our study included more pa-
tients with migraine than in other studies, the number was 
still not sufficient for a more-detailed comparison that also 
considered the subtypes of migraine. Third, the relationship 
between CH and migraine was judged based on the medical 
records and history-taking, and not in a prospective follow-up. 
In conclusion, this study found no significant differences 
in the characteristics of CH and its comorbidities according 
to the presence of comorbid migraine. However, the chronic 
CH subtype appeared more often with comorbid migraine, 
which may make the diagnosis of CH faster and easier. The 
correct management of both primary headache disorders re-
quires clinicians to check for the history of preceding mi-
graine or to follow up the occurrence of migraine during the 
diagnosis and management of CH. 
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